

Patent claims

1. Pharmaceutical compositions, containing as active compound a substance which inhibits the activity of TGF β on tumour cells of epithelial origin, for the treatment of epithelial, invasive tumour diseases, which are characterised by a reversible transition of the cells from an epithelial, non-invasive state into an invasive state.
2. Pharmaceutical compositions according to claim 1, containing as an additional active compound a substance which inhibits the expression or function of oncogenic Ras, and/or the overexpression of normal Ras and/or the activation of normal Ras by receptor tyrosinekinases in the cells.
3. Pharmaceutical compositions according to claim 2, containing as Ras inhibitor a substance which directly inhibits the activation of Ras.
4. Pharmaceutical compositions according to claim 1 or 2, containing as Ras inhibitor a substance which indirectly inhibits the activation of Ras.
5. Pharmaceutical compositions according to claim 4, characterised in that the substance is an inhibitor of a receptor-tyrosinekinase.
6. Pharmaceutical compositions according to claim 5, characterised in that the substance is an inhibitor of the EGF receptor.
7. Pharmaceutical compositions according to one of claims 1 to 6 for treating tumour diseases by

regulatory sequence of the plasminogen activator inhibitor.

- 5 14. Process according to claim 10, characterised in that the activity of test substances on the signal transmission pathway initiated by TGF β in the human cell is determined by measuring the modulation of the autophosphorylation of the TGF β receptor type II or its cytoplasmic domain by the test substance.
- 10 15. Process according to claim 10, characterised in that the activity of test substances on the signal transmission pathway initiated by TGF β in the human cell is determined by measuring the modulation, by the test substance, of the ability of the TGF β receptor type II to phosphorylate the TGF β receptor type I or its GS domain.
- 15